Aripiprazole Tablet
Product Images NDC 71335-1935

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 71335-1935). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole-fig-16.jpg (Aripiprazole Fig 16)

A line graph comparing the proportion of subjects with relapse over time between Aripiprazole and Placebo groups. The x-axis represents days from randomization up to 182 days, and the y-axis shows the proportion with relapse ranging from 0.0 to 1.0. The graph includes a number-at-risk table below the x-axis for each group at various time points.*

FDA Label Image

Aripiprazole-fig-17 (Aripiprazole Fig 17)

A line graph comparing the proportion of subjects with relapse over time (days from randomization) between Aripiprazole and placebo groups. The x-axis shows days up to 364, and the y-axis shows the proportion with relapse up to 1. The graph includes numbers of subjects at risk for each group at various time points below the x-axis.*

FDA Label Image

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)

A pharmacokinetic bar chart showing fold change and 90% confidence intervals for dehydro-aripiprazole under the influence of various inhibitors and other drugs. The chart compares the changes in AUC and Cmax relative to a reference without interacting drugs, for substances including ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam.*

FDA Label Image

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)

A forest plot chart illustrating fold change and 90% confidence intervals for various drugs and their pharmacokinetic parameters such as AUC and Cmax relative to a reference without interacting drug. The chart lists drugs including dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram, showing ratios near 1 with error bars for each measurement.*

FDA Label Image

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)

A pharmacokinetic chart illustrating Aripiprazole fold change with 90% confidence intervals for various factors including CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment. The chart displays changes in AUC and Cmax relative to a reference value across these categories.*

FDA Label Image

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)

A forest plot showing the fold change and 90% confidence intervals of dehydro-aripiprazole pharmacokinetic parameters (AUC and Cmax) across different variables: CYP2D6 metabolism status, gender, age, hepatic impairment, and severe renal impairment. The x-axis represents change relative to reference values.*

FDA Label Image

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)

A pharmacokinetic chart illustrating fold changes and 90% confidence intervals for aripiprazole's AUC and Cmax when co-administered with various inhibitors, inducers, and other drugs. The x-axis shows change relative to reference without interacting drug, and drug categories include CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs such as valproate, lithium, and lorazepam.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Fig8)

Chemical structure of the active ingredient Aripiprazole, showing its molecular framework with chlorine atoms, piperazine ring, and quinolinone moiety as depicted in the diagram.*

FDA Label Image

Aripiprazole-graph (Aripiprazole Graph)

A Kaplan-Meier survival curve graph depicting the proportion of subjects with relapse over days from randomization, comparing Aripiprazole and placebo groups. The solid blue line represents Aripiprazole, and the dashed red line represents placebo. The x-axis shows days from randomization (0 to 182), and the y-axis shows the proportion with relapse (0 to 1). A table below the graph lists the number of subjects at risk at various time points for both groups.*

FDA Label Image

Label (Lbl713351935)

Label for Aripiprazole 15 mg tablet by Bryant Ranch Prepack. The label indicates the product is a yellow round tablet, comparing to Abilify 15 mg tablet by Alkem Laboratories Limited. It includes storage instructions at room temperature 20°-25°C (68°-77°F) and a barcode with NDC 71335-1935.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.